Expanded evidence

• Analyzed a $120M+ federal portfolio to inform strategic planning and priority management.
• Authored 10+ federal white papers across Army DEVCOM, Navy DON STEM, NDEP, NSF, NIH, and related opportunities.
• Built and managed a five-agency opportunity pipeline, aligning technical concepts against agency priorities and BAAs.
• Established firm as an NSF-listed federal contractor, enabling direct federal engagement, and cultivated relationships with 10+ federal, industry, and DoD stakeholders.

Outcome context: No awards to date due to federal funding shifts beginning in late 2025.

Expanded evidence

• Supported an approximately $5M Fortune 500 research partnership, translating technical progress and risk for external PIs, VPs, scientists, and patent counsel.
• Delivered 50+ external research briefings to external executive leadership.
• Coordinated 3–5 concurrent funded projects and governed approximately $1.26M in research equipment; directed onboarding and technical development of 15+ researchers.
• First-author presenter at TMS 2024 on engineered peptide–iron interfaces, demonstrating peptide-mediated chelation and redox behavior across varying pH conditions.

Technical relevance: Research included engineered peptides interacting with Fe(III)/Fe(II), characterization of metal chelation and redox behavior, and peptide-mediated Fenton chemistry outside traditional operating conditions.

Translation relevance: Work routinely sat between experimental evidence, external industry priorities, technical risk, patent considerations, and potential applications.

Expanded evidence

• Reframed the proposal across 15+ academic, government, nonprofit, and private-sector stakeholders within a four-day submission window.
• Unified partner roles into a coherent operating and implementation model.
• Corrected inconsistencies across timelines, funding logic, evaluation metrics, and partner contributions.
• Surfaced external strategic intelligence that strengthened program positioning and credibility. Aligned metrics with federal opportunities.
• Awarded $325K July 2026.

Expanded evidence

• Diagnosed a 92-step commercial process and identified a 4.7× cascading failure pattern, shifting the leadership diagnosis from individual error to system architecture.
• Surfaced a 10-month client-feedback latency and defined a change approach for restoring the signal to leadership.
• Analyzed 2,000+ contracts to identify pricing variance and margin risk.
• Resolved a BD–Marketing conflict through a biomarker audit and 12-point survey with 100% participation.
• Built the business case that reversed an IT decision and restored collaboration tools for approximately 375 employees.